Business Wire

Yokogawa Survey Reveals Significant Impact of Industrial Autonomy on Environmental Sustainability

Share

Yokogawa Electric Corporation (TOKYO: 6841) reveals today the results of its latest survey* to gain further insights into the current and future state of industrial autonomy in process manufacturing. The survey highlights that the number of manufacturers moving forward with industrial autonomy is clearly increasing, and that there is a high awareness of the expected benefits on environmental sustainability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005054/en/

The global survey was conducted in seven markets (China, Germany, India, Japan, Saudi Arabia, SE Asia and the US) amongst 534 respondents from 390 companies in the chemical & petrochemical, life sciences, oil & gas, power generation, and renewable energy industry sectors.

Key insights
Regarding environmental sustainability, 45% of the respondents anticipate that industrial autonomy will have a significant impact and another 36% expect a moderate impact in the areas of dynamic energy optimization, water management, and emissions reduction. In contrast, only 6% expect industrial autonomy to have no impact at all on environmental sustainability.

The implementation of industrial autonomy projects is starting to gather pace, with 51% of the respondents surveyed now scaling deployment across multiple facilities and business functions and another 19% reporting they have deployed in at least one facility or business function.

While productivity improvements in production and manufacturing processes are expected to deliver the highest return on investment (ROI) in digital transformation over the next three years – with 31% ranking this area first and a further 20% ranking it second – health, safety and environment is emerging as a key area of ROI, with 26% ranking it first (13%) or second (13%).

With the ongoing COVID-19 pandemic, increasing remote operations capabilities represents a key factor in industrial autonomy. The survey reveals that one-third (33%) of manufacturers have deployed remote operations in single sites and 31% have implemented across multi-sites in connection to industrial autonomy.

C-level executives play a key role in plant-level autonomous planning, with the survey respondents saying that the Chief Executive Officer (38%), Chief Technical Officer (34%), and Chief Information Officer (31%) are the primary final decision-makers. These decision-makers are supported by senior level technical professionals, with 43% saying the Chief Digital Officer has significant influence on plant level autonomy decisions.

“It is gratifying to see from our latest survey that environmental sustainability is emerging as an area in which the shift from industrial automation to industrial autonomy, which we call IA2IA, is expected to make a significant positive impact,” explained Tsuyoshi Abe, senior vice president and head of the Marketing Headquarters at Yokogawa Electric. “Overall, however, our survey also indicates that one of the biggest challenges in implementing industrial autonomy is the lack of a clear roadmap, with almost half seeing it as their most significant challenge. This underlines the importance of a defined roadmap to industrial autonomy and finding the right partner to develop it.”

The survey report can be downloaded from the following website:
https://www.yokogawa.com/ia2ia/

* The "Global End-user Survey on the Implementation of Industrial Autonomy" was conducted on behalf of Yokogawa by research company Omdia in September 2021 among 534 respondents from 390 companies across seven global markets: China, Germany, India, Japan, Saudi Arabia, SE Asia, and the US. Respondents comprised manufacturers/end-users, OEMs, and systems integrators in the chemical & petrochemical, life sciences, upstream and mid-stream oil & gas, refining, power generation, and renewable energy power generation industry sectors. The survey respondents were in IT management, operations/project/plant management, and corporate management.

About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media inquiries:
PR Section,
Integrated Communications Center
Yokogawa Electric Corporation
E-mail: Yokogawa-pr@cs.jp.yokogawa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services5.1.2026 16:00:00 EET | Press release

The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/ The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations. Delaware Freeport, a provider of high-security, climate-controlled fine art storage, will operate as Delaware Freeport by DIETL, joining DIETL’s portfolio of trusted storage access points for

TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 15:54:00 EET | Press release

The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models from Microsoft (Phi 4 Reasoning Plus 14B), Alibaba (Qwen3 32B), and NVIDIA (Nemotron H 47B). This model release reaffirms TII’s position at the forefront of efficient AI innovation and reinforces the UAE’s growing influ

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release

Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release

Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release

Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye